INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular DystrophyGlobeNewsWire • 01/25/23
INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer's DiseaseGlobeNewsWire • 12/22/22
Wall Street Analysts Predict a 99% Upside in INmune Bio, Inc. (INMB): Here's What You Should KnowZacks Investment Research • 12/21/22
INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™GlobeNewsWire • 12/08/22
INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast CancerGlobeNewsWire • 12/06/22
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer's Disease TreatmentsGlobeNewsWire • 11/29/22
INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer's DiseaseGlobeNewsWire • 11/14/22
INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business UpdateGlobeNewsWire • 11/02/22
INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2GlobeNewsWire • 10/26/22
INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmuneGlobeNewsWire • 10/19/22
INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare ConferenceGlobeNewsWire • 09/07/22
INmune Bio, Inc's (INMB) CEO RJ Tesi on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
INmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business UpdateGlobeNewsWire • 08/03/22
INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3GlobeNewsWire • 07/27/22
INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer's DiseaseGlobeNewsWire • 07/25/22
INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming Resistance to HER2 Targeted Therapies in Breast CancerGlobeNewsWire • 06/16/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of INmune Bio, Inc. - INMBNewsfile Corp • 06/15/22
Can INmune Bio, Inc. (INMB) Climb 105% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 06/07/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of INmune Bio, Inc. - INMBNewsfile Corp • 05/28/22